Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus DOXY 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus DOXY 100.
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs DOXY 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subsalicylate exerts antimicrobial and anti-inflammatory effects via binding to gastrointestinal mucosa and inhibiting prostaglandin synthesis; metronidazole inhibits DNA synthesis by forming nitro radical anions; tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Each dose consists of 2 capsules (each containing bismuth subsalicylate 262.4 mg, metronidazole 250 mg, and tetracycline hydrochloride 375 mg) taken orally 3 times daily (after meals) for 10 days.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Bismuth subsalicylate: Bismuth component ~5 days (accumulation risk), salicylate 2–3 hours; Metronidazole: 8 hours (increased in hepatic impairment); Tetracycline HCl: 6–12 hours (prolonged in renal impairment).
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Bismuth subsalicylate: Renal excretion of salicylate and bismuth (bismuth largely fecal as insoluble sulfide); Metronidazole: Renal 60–80% (unchanged and metabolites), fecal 6–15%; Tetracycline HCl: Renal 60% unchanged, fecal 40% (biliary and direct excretion).
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic